News

The Gene Therapy Vector Facility at King’s College London is pleased to announce the addition of the Univercells Technologies’ scale-X™ carbo bioreactor to our GMP manufacturing portfolio, further strengthening our capabilities for adeno associated virus (AAV) and lentiviral vector (LV) production.

The scale-X carbo bioreactor is a fixed bed, single use bioreactor platform designed to support efficient and scalable adherent cell culture. Its compact footprint, high surface area, and modular design make it particularly well suited to viral vector manufacturing, enabling robust and reproducible production while supporting smooth scale up from development into GMP manufacture.

The introduction of the scale-X carbo platform will significantly enhance our ability to support technology transfer and scale up activities for both AAV and LV programmes. By offering a well-established and widely adopted bioreactor system, we can reduce development timelines, de risk process transfer, and provide greater flexibility for our current and future clients as programmes progress toward early clinical studies.

From a manufacturing perspective, the scale-X carbo bioreactor enables consistent process performance, efficient use of space, and streamlined operations within a GMP environment. These features support our commitment to delivering high quality viral vector while maintaining rigorous control of cost, quality, and timelines.

Our GMP team has successfully completed installation and qualification of the scale-X carbo bioreactor, ensuring readiness for GMP manufacturing. This milestone reflects the ongoing investment we are making in our infrastructure, processes, and people, and underlines our focus on providing reliable and flexible GMP viral vector supply for early phase gene therapy programmes.

We look forward to working with our partners to support the next generation of gene therapy development.

For further information on our capabilities and services, please contact henry.pegram(at)kcl.ac.uk.